covid-19 vaccine race Archives

AstraZeneca Paused COVID-19 Vaccine Trial as It Caused Unexplained Side Effect

The Phase 3 trial started on August 31 and enrolled about 30,000 participants at 80 locations. Now it is unclear how long the clinical hold will last. But it is obvious that other pharma companies will have to review their safety measures as well.

GAVI Vaccine Alliance Says $40 Would Be Maximum Price for COVID-19 Vaccine

Business News, Editor's Choice, Market News, News

By Darya Rudz Jul 28, 2020

There is a number of factors that will affect the COVID-19 vaccine price. They include technology, single or a double vaccine dose, as well as what yields from manufacturing facilities might be.

SNG Stock Soars 470% as Synairgen Reports Promising COVID-19 Vaccine Trial Results

Market News, News, Stocks, Story of the Day

By Darya Rudz Jul 20, 2020

Following the company’s announcement about the success of its COVID-19 vaccine, Synairgen stock has increased significantly. Now it is nearly 470% up.

Business News, Editor's Choice, Market News, News, Stocks

GlaxoSmithKline and Sanofi to Supply UK Government with 60M COVID-19 Vaccine Doses

By Darya Rudz Jul 6, 2020

Following the news, both Sanofi and GlaxoSmithKline stocks jumped. The latest closing price for Sanofi was $51.62. GlaxoSmithKline shares ended at $41.22 at the latest session.

Business News, Editor's Choice, Market News, News, Stocks

Pfizer (PFE), BioNTech (BNTX) Stocks Posititively Reacted to Coronavirus Vaccine Trial

By Darya Rudz Jul 2, 2020

Following the positive news, Pfizer and BioNTech shares managed to jump 5% and 2.2% accordingly on Wednesday. PFE closed with a 3% rise while BTNX lost 4%.

Business News, Market News, News, Stocks, Wall Street

AZN Stock Up 0.6%, WHO Marks AstraZeneca and Moderna as Leaders in Race for COVID-19 Vaccine

By Chuks Chukwuka Jun 29, 2020

The World Health Organization highlighted the progress of AstraZeneca seeking for the COVID-19 vaccine. UK-based company has moved to the human trial stage. Moderna is not far behind.

Business News, Market News, News, Stocks

Why Vaxart, Inovio Pharmaceuticals, and Sorrento Therapeutics Stocks Took Off on Thursday

By Darya Rudz Jun 26, 2020

The number of COVID-19 cases is rising again, and the companies working on the vaccine will likely further benefit from a cash flow into them. Vaxart, Inovio Pharmaceuticals, and Sorrento Therapeutics stocks are good examples of this advantage.

Business News, Editor's Choice, Market News, News, Stocks

Moderna (MRNA) Stock Rises 2.59%, mRNA-1273 Vaccine Will Be Ready for Distribution in 2021

By Darya Rudz Jun 19, 2020

Following Moderna CEO’s big expectations on mRNA-1273 distribution, Moderna shares jumped. On June 18, Moderna stock rose by 2.59% to close at $64.95. In pre-market today, Moderna shares are 0.08% up.

Business News, Editor's Choice, Market News, News, Stocks

AZN Stock Up 0.68% Now, AstraZeneca to Deliver 400M Doses of COVID-19 Vaccine to Europe

By Darya Rudz Jun 15, 2020

Within AstraZeneca’s agreement with Europe’s Inclusive Vaccines Alliance (IVA), France, Germany, Italy, and the Netherlands will accelerate the supply of the vaccine. AZN stock is up in the pre-market today.

Business News, Deals News, Market News, News, Stocks

AstraZeneca Adressed Gilead Sciences to Discuss Potential Merger

By Darya Rudz Jun 8, 2020

If combined, AstraZeneca and Gilead Sciences would have a market capitalization of about $237 billion, exceeding Merck & Co and Pfizer worth $207 billion and $200 billion respectively.

Business News, Market News, News, Stocks, Wall Street

Gilead Sciences (GILD) Stock Rose 1.5% Yesterday on Remdesivir $7 Billion Sales Prognosis

By Darya Rudz Jun 4, 2020

According to SVB Leerink analyst Geoffrey Porges, remdesivir price is likely to be $5,000 per course in the US, $4,000 per course in Europe, and around $2,000 in other markets. Gilead Sciences (GILD) stock keeps rising.

Editor's Choice, Market News, News, Stocks

AstraZeneca and Oxford University COVID-19 Vaccine Trial: 50% Chance of Success Predicted

By Darya Rudz May 25, 2020

While the COVID-19 vaccine candidate of Oxford University and AstraZeneca has proved to be effective in the pre-clinical study, scientists warn it has a 50% chance of success and may return “no result”.